Lisinopril therapy for hemodialysis hypertension: Hemodynamic and endocrine responses

Agarwal Rajiv, Lewis Rebecca, Joyce L. Davis, Becker Bruce

Research output: Contribution to journalArticle

52 Scopus citations


To evaluate the antihypertensive effects of lisinopril, a renally excreted angiotensin-converting enzyme inhibitor, we assessed supervised administration of the drug after hemodialysis (HD) three times weekly. Blood pressure (BP) was assessed by interdialytic 44-hour ambulatory BP (ABP) monitoring, and endocrine responses were assessed by plasma renin activity (PRA) before and after dialysis. Lisinopril dose was titrated at biweekly intervals. If this was not effective after full titration (lisinopril to 40 mg three times weekly), ultrafiltration was added to reduce dry weight. The primary outcome variable was change In BP from the end of the run-in period to the end of the study. No change in mean ABP was noted during run-in. However, mean 44-hour ABP decreased from 149 ± 14 (SD)/84 ± 9 to 127 ± 16/73 ± 9 mm Hg, a decrease of 22/11 mm Hg (P < 0.001) at final evaluation. Of 11 patients who completed the trial, only 2 patients had systolic hypertension (≥135 mm Hg) and 1 patient had diastolic hypertension (≥85 mm Hg) at the final visit. Four patients were administered 10 mg of lisinopril; 5 patients, 20 mg; and 2 patients, 40 mg; only 1 of these patients required ultrafiltration therapy. There was a persistent antihypertensive effect over 44 hours. BP reduction was achieved without an increase in intradialytic symptomatic or asymptomatic hypotensive episodes. PRA increased in response to dialysis, as well as lisinopril. In conclusion, supervised lisinopril therapy is effective in controlling hypertension in chronic HD patients. This may be related to blockade of angiotensin II generation by kidneys despite the loss of excretory function.

Original languageEnglish (US)
Pages (from-to)1245-1250
Number of pages6
JournalAmerican Journal of Kidney Diseases
Issue number6
StatePublished - 2001


  • Ambulatory blood pressure monitoring (ABPM)
  • Anglotensin-converting enzyme (ACE) inhibitors
  • Antihypertensive therapy
  • Hemodialysis (HD)
  • Hypertension
  • Reninangiotensin system

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Lisinopril therapy for hemodialysis hypertension: Hemodynamic and endocrine responses'. Together they form a unique fingerprint.

  • Cite this